Comparison of the Performance of 18F-FDG PET/CT With That of Labeled Leukocyte Scintigraphy in the Follow-up of Malignant Otitis Externa.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Malignant Otitis Externa
- Sponsor
- Central Hospital, Nancy, France
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- 18F-FDG positron emission tomography
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy in patients with a malignant otitis externa.
Detailed Description
The management of malignant otitis externa (MEO) is a major issue in patients who are often polypathological and fragile. Appropriate antibiotic therapy must be started quickly after the diagnosis is made and followed for a period of at least 6 weeks. Imaging plays a major role in assessing the extent of the infection and especially healing, after 6 weeks of antibiotic therapy. The persistence of an infection at the end of the treatment, observed in imaging, will allow a change of antibiotic line. This study consists in studying in a population affected by an OEM, the performance of PET/CT with 18F-FDG compared to scintigraphy with labeled leukocytes. The usefulness of the latter in the follow-up of the pathology after antibiotic therapy has already been proven in the literature. The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy.
Investigators
Antoine VERGER
MD, PhD
Central Hospital, Nancy, France
Eligibility Criteria
Inclusion Criteria
- •patients with malignant otitis externa who received a 18F-FDG positron emission tomography and a labelled leukocyte scintigraphy
Exclusion Criteria
- •patients who refuse to have their imaging data used
Outcomes
Primary Outcomes
18F-FDG positron emission tomography
Time Frame: one day
measurement of standard uptake value
Labeled leukocyte scintigraphy
Time Frame: one day
measurement of standard uptake value